BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ICG415 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ICG415\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07668557-2969@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:ICG415: Phase 1 readout est. (NCT07668557)
DESCRIPTION:ICG415\, phase 1\, Acute Myeloid Leukemia.\nStudy: Anti-CD33-CL
 L1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Mye
 loid Leukemia\nEstimated primary completion: 4 July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/icg415#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07668557
URL:https://assetmemo.bio/drug/icg415#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
